These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 34784300)

  • 1. PD-1 blockade counteracts post-COVID-19 immune abnormalities and stimulates the anti-SARS-CoV-2 immune response.
    Loretelli C; Abdelsalam A; D'Addio F; Ben Nasr M; Assi E; Usuelli V; Maestroni A; Seelam AJ; Ippolito E; Di Maggio S; Loreggian L; Radovanovic D; Vanetti C; Yang J; El Essawy B; Rossi A; Pastore I; Montefusco L; Lunati ME; Bolla AM; Biasin M; Antinori S; Santus P; Riva A; Zuccotti GV; Galli M; Rusconi S; Fiorina P
    JCI Insight; 2021 Dec; 6(24):. PubMed ID: 34784300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation.
    Roberts A; Bentley L; Tang T; Stewart F; Pallini C; Juvvanapudi J; Wallace GR; Cooper AJ; Scott A; Thickett D; Lugg ST; Bancroft H; Hemming B; Ferris C; Langman G; Robinson A; Chapman J; Naidu B; Pinkney T; Taylor GS; Brock K; Stamataki Z; Brady CA; Curnow SJ; Gordon J; Qureshi O; Barnes NM
    Sci Rep; 2021 Feb; 11(1):4030. PubMed ID: 33597595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the humoral and cellular immune response after a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors with or without chemotherapy: an update after 6 months of follow-up.
    Lasagna A; Lilleri D; Agustoni F; Percivalle E; Borgetto S; Alessio N; Comolli G; Sarasini A; Bergami F; Sammartino JC; Ferrari A; Zavaglio F; Arena F; Secondino S; Falzoni M; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Feb; 7(1):100359. PubMed ID: 34973510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Exhaustion of HBV-Specific CD8 T Cells Impedes PD-L1 Blockade Efficacy in Chronic HBV Infection.
    Ferrando-Martinez S; Snell Bennett A; Lino E; Gehring AJ; Feld J; Janssen HLA; Robbins SH
    Front Immunol; 2021; 12():648420. PubMed ID: 34589081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and functional analysis of an anticancer T-cell medicine with immune checkpoint inhibitory ability.
    Fujiwara K; Shigematsu K; Tachibana M; Okada N
    IUBMB Life; 2020 Aug; 72(8):1649-1658. PubMed ID: 32255257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct SARS-CoV-2 specific NLRP3 and IL-1β responses in T cells of aging patients during acute COVID-19 infection.
    Mahalingam SS; Jayaraman S; Arunkumar A; Dudley HM; Anthony DD; Shive CL; Jacobson JM; Pandiyan P
    Front Immunol; 2023; 14():1231087. PubMed ID: 37799713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
    Gray KD; McCloskey JE; Vedvyas Y; Kalloo OR; Eshaky SE; Yang Y; Shevlin E; Zaman M; Ullmann TM; Liang H; Stefanova D; Christos PJ; Scognamiglio T; Tassler AB; Zarnegar R; Fahey TJ; Jin MM; Min IM
    Clin Cancer Res; 2020 Nov; 26(22):6003-6016. PubMed ID: 32887724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-γ
    Vallejo A; Vizcarra P; Quereda C; Moreno A; Casado JL;
    Eur J Clin Invest; 2021 Dec; 51(12):e13636. PubMed ID: 34164811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8
    Peña-Asensio J; Calvo H; Torralba M; Miquel J; Sanz-de-Villalobos E; Larrubia JR
    Cells; 2021 Mar; 10(3):. PubMed ID: 33802622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1-Expressing SARS-CoV-2-Specific CD8
    Rha MS; Jeong HW; Ko JH; Choi SJ; Seo IH; Lee JS; Sa M; Kim AR; Joo EJ; Ahn JY; Kim JH; Song KH; Kim ES; Oh DH; Ahn MY; Choi HK; Jeon JH; Choi JP; Kim HB; Kim YK; Park SH; Choi WS; Choi JY; Peck KR; Shin EC
    Immunity; 2021 Jan; 54(1):44-52.e3. PubMed ID: 33338412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
    Zhang X; Shi X; Li J; Hu Z; Gao J; Wu S; Long Z
    Cancer Sci; 2019 Jan; 110(1):31-39. PubMed ID: 30343514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: Clinical Management of a Patient With Metastatic Non-Small Cell Lung Cancer Newly Receiving Immune Checkpoint Inhibition During Symptomatic COVID-19.
    Mellinghoff SC; Vanshylla K; Dahlke C; Addo MM; Cornely OA; Klein F; Persigehl T; Rybniker J; Gruell H; Bröckelmann PJ
    Front Immunol; 2021; 12():798276. PubMed ID: 34987520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune characterization of a Colombian family cluster with SARS-CoV-2 infection.
    Aguilar-Jiménez W; Flórez-Álvarez L; Rincón DS; Marín-Palma D; Sánchez-Martínez A; Martínez J; Zapata MI; Loaiza JD; Cárdenas C; Guzmán F; Velilla PA; Taborda NA; Zapata W; Hernández JC; Díaz FJ; Rugeles MT
    Biomedica; 2021 Oct; 41(Sp. 2):86-102. PubMed ID: 34669281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
    Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
    Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.
    Ikematsu Y; Tanaka K; Yanagihara T; Liu R; Inoue H; Yoneshima Y; Ota K; Iwama E; Takata S; Hata K; Takahata Y; Wataya H; Nakanishi Y; Okamoto I
    Lung Cancer; 2019 Dec; 138():58-64. PubMed ID: 31639551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed Cell Death Protein-1 Regulation in Response to SARS-CoV-2 in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2: A Prospective Cohort Study.
    Opoka-Winiarska V; Grywalska E; Morawska-Michalska I; Korona-Głowniak I; Kądziołka O; Gosik K; Majchrzak A; Rahnama-Hezavah M; Niedźwiedzka-Rystwej P
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38892153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-the-Shelf Partial HLA Matching SARS-CoV-2 Antigen Specific T Cell Therapy: A New Possibility for COVID-19 Treatment.
    Kim N; Lee JM; Oh EJ; Jekarl DW; Lee DG; Im KI; Cho SG
    Front Immunol; 2021; 12():751869. PubMed ID: 35003063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical COVID-19 is associated with distinct leukocyte phenotypes and transcriptome patterns.
    Christensen EE; Jørgensen MJ; Nore KG; Dahl TB; Yang K; Ranheim T; Huse C; Lind A; Nur S; Stiksrud B; Jenum S; Tonby K; Holter JC; Holten AR; Halvorsen B; Dyrhol-Riise AM
    J Intern Med; 2021 Sep; 290(3):677-692. PubMed ID: 34080738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.